There is no cure for FOP, and bone that has already formed can't be safely removed, because surgery triggers even more bone growth. But 2026 changed the outlook. Three FDA-approved drugs now reduce new bone formation, each blocking the same faulty signal. Our view: the cure will come from shutting that signal down in early childhood, before extra bone builds up, and one day correcting the gene itself.
This is Cure Checker's editorial assessment of published evidence, not medical advice. FOP care should be guided by an FOP-experienced physician. IFOPA can help connect families with experts.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your FOP-experienced physician.
Could a trigger-blocking drug, given before and after an operation, let surgeons remove bone that locks a joint without new bone growing back? If a small, closely watched trial in people already on treatment showed no regrowth on scans a year later, freeing locked joints could become a goal, not just stopping new bone. Today's expert advice to avoid this surgery still stands; the idea should only ever be tested in a carefully run trial.
What would prove it wrong: if bone grows back at the surgery site even with the drug fully blocking the faulty signal, or if wounds fail to heal.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
In a registry of 114 people with genetically confirmed FOP, 34.5% waited more than 3 years for a diagnosis, 63.2% were first misdiagnosed (half as a tumor), and 80.4% of those who had a biopsy reported worsening afterward. The authors call for checking the great toes early and avoiding biopsy. A study of the diagnosis path, not a treatment.
Lab study: cells with the FOP gene change made more of a signaling protein called CCN2. An antibody against it (pamrevlumab) lowered abnormal bone growth in a mouse model. Early lab work, not tested in people with FOP.
The peer-reviewed report of the Phase 3 trial of garetosmab, an antibody that blocks activin A, which led to its August FDA approval.
Third FDA-approved FOP drug, for ages 12 and up. The first approved on Phase 2 data (PROGRESS, 63 patients, 81% fewer patients with new lesions).
A study of 250 U.S. people with FOP (2017-2023) found a median age at death of 50.5 years versus 80.5 in the general population. Authors include Regeneron employees (maker of garetosmab); it looked at past data, not any treatment.
For adults, to reduce new bone lesions and clinician-assessed flare-ups. Based on the Phase 3 OPTIMA trial.
A possible European approval for an FOP drug, after Europe refused palovarotene in 2023.
Repurposed ALK2 inhibitor. Phase 2 results were expected in summer 2026.
Based on OPTIMA: 94% (3 mg/kg) and 90% (10 mg/kg) fewer new bone lesions versus placebo at 56 weeks.
Before 2023 there was no approved FOP treatment anywhere in the U.S. Now there are three. They prevent new bone, but they can't remove bone that's already formed.
A once-daily ALK2-blocking pill. In the PROGRESS trial (63 patients), 81% fewer patients formed new bone lesions at week 24. New bone volume shrank slightly (−3.2 cm³), while it grew by 24.6 cm³ on placebo. U.S. availability is expected in October 2026.
A monthly infusion that blocks activin A. In OPTIMA (63 adults), new bone lesions fell 90–94% and total new bone volume by more than 99% compared with placebo. Clinician-assessed flare-ups also dropped sharply.
The first FOP drug, a pill that reduces new bone formation. It can cause early closure of growth plates in children, so it's limited by age and needs monitoring. Europe refused it.
Pediatric cohorts are under way. Treating before bone builds up is the best hope for preserving movement.
An ALK2-blocking drug originally developed for cancer. Phase 2 results were expected in 2026.
Ipsen's ALK2 inhibitor trial was ended in December 2025.
| Care | For | What it does |
|---|---|---|
| Garetosmab, zilurgisertib, palovarotene | Preventing new bone | Reduce new bone formation. Which drug fits depends on age and preference (infusion or pill). |
| Short course of steroids | Early flare-ups | Started within 24 hours of a flare-up affecting major joints, to calm swelling. Doesn't stop bone overall. |
| Trigger avoidance | Everyone | No muscle injections or biopsies, careful dental anesthesia, fall prevention, specialist anesthesia for surgery. |
| Breathing & mobility support | Advanced disease | Monitoring lung function, adaptive equipment and occupational therapy. |
No supplement or natural remedy slows FOP. The most powerful things families can do are about preventing injury. We rate each by the strength of evidence.
Use other routes for vaccines and medicines when possible. Biopsies of FOP lumps can trigger new bone.
Soft surfaces, home modifications and helmets for children reduce the injuries that start flare-ups.
Jaw stretching and nerve-block injections can lock the jaw. Choose a dentist who follows FOP guidance.
Low-impact movement and warm-water therapy can support well-being. Avoid forceful stretching or massage of stiff areas.
Healthy intake supports normal bone. There's no evidence that limiting or boosting them changes extra bone formation.
No supplement removes FOP bone. Don't take high-dose vitamin A products (palovarotene is a vitamin A-like drug).
Be careful: surgery to remove extra bone usually causes more bone to form. Any operation or dental work should be planned with an FOP expert. Carry an FOP medical alert card.
Centers recognized for expertise in this condition, and communities of people living with it.
A listed study site in registered trials of FOP medicines, including palovarotene.
A listed study site in registered trials of the FOP medicine palovarotene.
A listed study site in registered trials of the FOP medicine palovarotene.
A listed study site in registered trials of FOP medicines, including palovarotene and garetosmab.
A listed study site in registered trials of FOP medicines, including palovarotene and garetosmab.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
FOP is very rare, so finding others who understand can be life-changing. The FOP community is small, close and international.
A peer support group for adults with FOP and a caregiver support group, led by the International FOP Association.
Join a group ↗The global FOP association: a patient registry, expert connections, family gatherings and resources in many languages.
Get connected ↗A UK charity that supports families, funds research and holds an annual family gathering.
Visit ↗Community-run family groups. This link searches Facebook (a login is required).
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your FOP physician. Think about your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Access to FOP drugs is very uneven. Canada approved the first one before the U.S. Europe refused it. As of October 2026, the two newest drugs are approved only in the U.S.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Palovarotene (Sohonos)Children 8/10+ and adults | 2023 | Refused | — | 2022 | — | — | — | — | — |
| Garetosmab (Pasatru)Adults | 2026 | — | — | — | — | — | — | — | — |
| Zilurgisertib (Atebrioz)Ages 12+ | 2026 | Under review | — | — | — | — | — | — | — |
Health Canada approved palovarotene about 19 months before the FDA, making it the world's first approved FOP treatment.
The EMA turned down palovarotene, citing insufficient efficacy data. It accepted zilurgisertib for review in August 2026, so European families may finally get an option.
The UAE is among the few countries besides the U.S. and Canada where palovarotene is approved.
FOP is caused by a change in one gene, ACVR1. It makes a bone-signaling receptor overactive, so after an injury or "flare-up," muscles, tendons and ligaments slowly turn into bone. Over time, a second skeleton locks joints in place.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
This organization helps people living with FOP pay for equipment and changes that make daily life easier. Funds are limited and rules vary, so contact it directly.
The Harold and Elaine Kaplan awards pay for adaptive equipment, home changes, tuition and aids for comfort, school, work, communication or mobility, up to a lifetime total of $1,800 per person. Applications open in two cycles a year (January and July), and import or legal rules can block some countries.
See the awards ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 2, 2026.
The flare-up triggers, the steroid-within-24-hours practice, the injury-avoidance guidance (from the International Clinical Council on FOP), the 2006 gene discovery, the "mid-50s" life expectancy and the big-toe sign reflect the established published record. They don't yet have individual citations here. Expert care centers: The patient organization's list of FOP centers could not be opened, so these entries rest on being listed sites in registered trials, not on a formal designation or on leading the trial. Financial help: checked October 6, 2026. Only one qualifying organization was found. IFOPA's main award page blocks automated reading, so this card is based on IFOPA's own guidebook page (which still shows 2025 dates) and FOP Friends' description of the program. FOP Friends (UK) states it does not give grants to individuals.